Publications by authors named "David Alexander Ziegler"
Article Synopsis
- Esophageal cancer has a poor prognosis, and while neoadjuvant chemoradiotherapy (CRT) followed by immunotherapy shows promise, the effect of CRT on PD-L1 expression in these cancers is not fully understood.
- The study investigated PD-L1 expression changes in esophageal adenocarcinoma and squamous cell carcinoma cell lines after treatment with chemotherapy and CRT, finding that Carboplatin and CRT led to the highest increases in PD-L1 expression.
- Despite observed increases in PD-L1 with certain treatments, the overall conclusion was that neoadjuvant CRT according to the CROSS protocol did not significantly alter PD-L1 expression when comparing pre- and post-treatment levels in patient samples.
In this study, we investigated the outcomes and factors influencing treatment efficacy in 93 patients with limited disease small cell lung cancer (LD-SCLC), with a median age of 64 years. We focused on the impact of chemotherapy regimens, prophylactic cranial irradiation (PCI), and patient-related variables. The median follow-up for OS was 17.
View Article and Find Full Text PDFArticle Synopsis
- Identifying the best treatment for elderly patients with localized non-small cell lung cancer (NSCLC) is difficult, but low-dose cisplatin chemotherapy is a potential option with less toxicity.
- In a study comparing patients aged 70 and older to younger ones, elderly patients had more health issues and lower stages of cancer, but they experienced fewer severe side effects with low-dose cisplatin compared to cisplatin/vinorelbine.
- To improve survival outcomes for elderly patients, multimodal treatment strategies, including surgery and systemic therapy, should be considered, and the use of low-dose cisplatin should be tailored to each patient due to its acceptable toxicity profile.
And Yet It Moves: Clinical Outcomes and Motion Management in Stereotactic Body Radiation Therapy (SBRT) of Centrally Located Non-Small Cell Lung Cancer (NSCLC): Shedding Light on the Internal Organ at Risk Volume (IRV) Concept.
Cancers (Basel)
January 2024
The internal organ at risk volume (IRV) concept might improve toxicity profiles in stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC). We studied (1) clinical aspects in central vs. peripheral tumors, (2) the IRV concept in central tumors, (3) organ motion, and (4) associated normal tissue complication probabilities (NTCPs).
View Article and Find Full Text PDFPatterns of Pretreatment Diagnostic Assessment in Patients Treated with Stereotactic Body Radiation Therapy (SBRT) for Non-Small Cell Lung Cancer (NSCLC): Special Characteristics in the COVID Pandemic and Influence on Outcomes.
Curr Oncol
February 2022
The pandemic raised a discussion about the postponement of medical interventions for non-small cell lung cancer (NSCLC). We analyzed the characteristics of pretreatment diagnostic assessment in the pandemic and the influence of diagnostic assessment on outcomes. A total of 96 patients with stereotactic body radiation therapy (SBRT) for NSCLC were included.
View Article and Find Full Text PDF